Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
Poxel SA, has announced that during a human hyperglycemic clamp trial, Imeglimin, a novel compound in development to treat Type 2 diabetes, increases insulin secretion in response to glucose, confirming previous preclinical and clinical results. Imeglimin acts directly on the three main organs affected by type 2 diabetes: the pancreas, the liver and the muscle. This mechanism makes Imeglimin unique among the current anti-diabetic agents available to physicians.
Poxel's objective was to confirm, in diabetic patients, Imeglimin's impact on glucose-stimulated insulin secretion, using the reference method of hyperglycemic clamp technique, including arginine stimulation to assess maximal secretory capacity. This clinical pharmacology trial was a randomized, double-blind, placebo-controlled, parallel-group study investigating insulin secretion after Imeglimin chronic treatment. The trial included 30 patients; 15 per group. Results showed that Imeglimin met the primary and secondary endpoints, with a statistically significant increase in the incremental area under the curve of insulin response to glucose (iAUC0-45min insulin) and a statistically significant increase in the incremental area under the curve of C-peptide and proinsulin response (iAUC0-45min C-peptide, iAUC0-45min proinsulin), in comparison to placebo.
Professor Michael Roden, Poxel Scientific Board member, commented, "Imeglimin is a very interesting novel agent, which, by improving glucose sensing of the pancreatic beta cell, increases glucose-stimulated insulin secretion and this contributes to the glucose lowering action of Imeglimin . Given the activity of Imeglimin on both liver and muscle demonstrated in preclinical studies, Imeglimin has a unique mechanism of action that could represent a new way of addressing the pathophysiology underlying Type 2 diabetes".
Thomas Kuhn, CEO of Poxel added, "These positive data reinforce Imeglimin's fully differentiated profile as a new anti-diabetic agent. No other single agent impacts the three main organs involved in this chronic disease, which means Imeglimin can be combined with any current diabetes treatments. This potential was already evidenced in two clinical trials in combination with the two most important molecules on the market today, metformin and sitagliptin. Combining treatments to control glycaemia is now at the cornerstone of Type 2 diabetes management".
Imeglimin is the first in a new chemical class of oral anti-diabetic agents, the glimins. Imeglimin acts on three main target organs involved in glucose homeostasis: the liver, muscle, and the pancreas and has therefore a distinct mode of action compared to existing treatments for Type 2 diabetes. In that, it looks like the best partner to complement other treatments. Imeglimin phase 2a monotherapy results were published in Diabetes, Obesity and Metabolism in April 2012. In October 2011, Poxel reported phase 2 results of Imeglimin as add-on therapy to metformin in patients inadequately controlled with metformin monotherapy. This study achieved its primary end-point of superiority in HbA1c reduction versus placebo (p<0.001). The study results are published in Diabetes Care. In November 2012, Poxel reported phase 2 results of Imeglimin as add-on therapy to sitagliptin in patients inadequately controlled with sitagliptin monotherapy. This study achieved its primary end-point of superiority in HbA1c reduction versus placebo (p<0.001). The study results, presented at ADA meeting in Chicago this year, are under review by a diabetes peer-reviewed journal.About Type 2 Diabetes
Type 2 diabetes is the most common type of diabetes. It usually occurs in adults, but is increasingly seen in children and adolescents. In type 2 diabetes, the body is able to produce insulin but it is either not sufficient or the body is not responding to its effects, leading to a build-up of glucose in the blood. Type 2 diabetes is a major cause of both cardiovascular and kidney diseases.
The number of people with type 2 diabetes is rising rapidly worldwide. This rise is associated with economic development, ageing populations, increasing urbanisation, dietary changes, reduced physical activity and changes in other lifestyle patterns.
The International Diabetes Federation estimates that in 2011, 366 million people around the world have diabetes. This total is expected to rise to 552 million in 2030. Each year a further 7 million people develop diabetes. The current market is dominated by few product classes and significant unmet needs remain for both physicians and patients.
The worldwide pharmaceutical market for Type 2 diabetes, 60% of which is represented by oral anti-diabetics, is expected to increase from $31 billion in 2012 to $48.8 billion in 2021 (source IMS audits).
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Diabetes category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Poxel. "Poxel's anti-diabetic Imeglimin confirms its unique mechanism of action in type 2 diabetic patients." Medical News Today. MediLexicon, Intl., 10 Oct. 2013. Web.
6 Dec. 2013. <http://www.medicalnewstoday.com/releases/267207>
Poxel. (2013, October 10). "Poxel's anti-diabetic Imeglimin confirms its unique mechanism of action in type 2 diabetic patients." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact the our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/267207.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2013 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.